Lillebaelt Hospital

At Lillebaelt Hospital the Department of Medicine is conducting studies that aim to improve outcomes for patients with acute heart events and stroke risk. Researchers are testing new interventions to boost the return of spontaneous circulation during in‑hospital cardiac arrest and evaluating oral anticoagulant strategies to prevent ischemic stroke after a recent non‑cardioembolic stroke or high‑risk transient ischemic attack. Additional trials compare novel agents with established therapy to reduce stroke and systemic embolism in people with atrial fibrillation.

• Evaluation of sodium bicarbonate in cardiac arrest resuscitation
• Oral FXIa inhibitor asundexian for secondary stroke prevention
• Comparison of asundexian versus apixaban for stroke prevention in atrial fibrillation

With 29 investigators involved, the site is advancing cardiovascular care through rigorous, patient‑focused research.

The hospital’s research program includes a platform dedicated to acute respiratory infections in hospitalized adults. This initiative, known as STRIVE, supports randomized trials that assess the safety and efficacy of various treatment strategies, including immune‑modulating approaches for patients with severe respiratory illness.

• Immune modulation strategy trial for hospitalized patients with respiratory infections
• Assessment of early therapeutic interventions to improve clinical recovery
• Evaluation of safety outcomes across multiple respiratory infection trials

The collaborative framework enables rapid testing of promising therapies, aiming to reduce morbidity from serious lung conditions.

In response to the ongoing pandemic, Lillebaelt Hospital is conducting studies that target COVID-19 in the inpatient setting. One trial investigates whether adding a second intramuscular dose of an investigational product to standard care can accelerate clinical recovery up to Day 60 compared with placebo.

• Early administration of a second intramuscular dose in COVID‑19 patients
• Comparison of clinical recovery trajectories between treatment and placebo groups
• Safety monitoring of the investigational strategy in hospitalized adults

These efforts contribute to a better understanding of effective viral disease management and support public health initiatives.